Intercept Pharmaceuticals (NASDAQ:ICPT) Upgraded at ValuEngine

ValuEngine upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a buy rating in a research report released on Thursday, ValuEngine reports.

Other equities research analysts have also issued reports about the stock. Oppenheimer decreased their target price on shares of Intercept Pharmaceuticals from to in a research note on Wednesday, February 26th. Wells Fargo & Co reiterated an overweight rating and set a $146.00 target price (up from $120.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. SVB Leerink reiterated an underperform rating on shares of Intercept Pharmaceuticals in a research note on Thursday, January 2nd. Cantor Fitzgerald reiterated a buy rating and set a $186.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Bank of America initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, March 5th. They set a neutral rating and a $111.00 target price for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $146.53.

NASDAQ ICPT traded up $4.10 during mid-day trading on Thursday, reaching $62.85. The stock had a trading volume of 611,816 shares, compared to its average volume of 595,155. Intercept Pharmaceuticals has a 1 year low of $47.57 and a 1 year high of $125.00. The stock has a market cap of $1.93 billion, a PE ratio of -5.77 and a beta of 1.77. The company has a fifty day moving average price of $78.90 and a 200 day moving average price of $88.36. The company has a debt-to-equity ratio of 10.32, a current ratio of 4.45 and a quick ratio of 4.45.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Tuesday, February 25th. The biopharmaceutical company reported ($2.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.47). Intercept Pharmaceuticals had a negative return on equity of 455.79% and a negative net margin of 136.78%. The firm had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $68.19 million. During the same quarter in the previous year, the firm earned ($2.97) earnings per share. Intercept Pharmaceuticals’s revenue was up 34.2% on a year-over-year basis. As a group, equities research analysts expect that Intercept Pharmaceuticals will post -11.01 earnings per share for the current year.

In related news, insider Jason Campagna sold 732 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $113.02, for a total value of $82,730.64. Following the completion of the transaction, the insider now owns 6,303 shares of the company’s stock, valued at approximately $712,365.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christian Weyer sold 723 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $94.04, for a total transaction of $67,990.92. Following the completion of the transaction, the executive vice president now directly owns 18,560 shares of the company’s stock, valued at approximately $1,745,382.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,568 shares of company stock valued at $160,623. Insiders own 5.00% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC bought a new position in Intercept Pharmaceuticals in the 3rd quarter worth $36,000. Edge Wealth Management LLC bought a new position in Intercept Pharmaceuticals in the 4th quarter worth $37,000. Nisa Investment Advisors LLC boosted its holdings in Intercept Pharmaceuticals by 200.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 300 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 200 shares during the period. Kistler Tiffany Companies LLC boosted its holdings in Intercept Pharmaceuticals by 33.3% in the 4th quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 100 shares during the period. Finally, Sowell Financial Services LLC boosted its holdings in Intercept Pharmaceuticals by 469.6% in the 4th quarter. Sowell Financial Services LLC now owns 655 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 540 shares during the period. 78.66% of the stock is owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Recommended Story: How much money do you need to begin day trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.